Before understanding tirzepatide-class compounds, you need to understand incretins. Incretins are hormones released by the gut after eating that signal the pancreas to produce insulin. The two primary incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, they account for approximately 50-70% of the insulin released after a meal in healthy individuals — a phenomenon called the "incretin effect."¹

GLP-1 and GIP work through different receptors and produce overlapping but distinct biological effects. GLP-1 receptor activation reduces appetite, slows gastric emptying, and stimulates glucose-dependent insulin release. GIP receptor activation promotes glucose-dependent insulin secretion through a different intracellular pathway and has additional effects on fat tissue, bone density, and nutrient absorption.

For decades, metabolic research focused almost exclusively on GLP-1. The GLP-1 receptor agonist class (which includes semaglutide, the active compound in Ozempic and Wegovy) became one of the most successful drug classes in metabolic medicine. GIP received comparatively less attention — partly because early research suggested that GIP receptor signaling was impaired in type 2 diabetes, leading some researchers to believe it was a less viable therapeutic target.

Tirzepatide-class compounds challenged that assumption by targeting both receptors simultaneously.

The rationale behind dual GIP/GLP-1 agonism is straightforward: if two incretin pathways regulate metabolism through complementary mechanisms, activating both should produce broader or greater metabolic effects than activating either alone.

This hypothesis was tested — and largely confirmed — in a series of preclinical and clinical studies.²

In rodent models, dual agonists produced greater improvements in glucose tolerance, insulin sensitivity, and body weight reduction than equi-effective doses of GLP-1-only agonists. The GIP component appeared to contribute additional effects on adipose tissue metabolism and energy expenditure that were absent with GLP-1 agonism alone.

The key mechanistic question was whether GIP receptor activation simply added its own effects on top of GLP-1 effects (additive), or whether the combination produced something qualitatively different (synergistic). Preclinical data suggests elements of both — some metabolic endpoints show simple addition, while others (particularly body weight and visceral fat reduction) show responses that exceed the sum of individual effects.³

Tirzepatide-class compounds have been extensively studied in human clinical trials — providing a level of evidence rare in the peptide research space.

SURPASS Program (Type 2 Diabetes)

The SURPASS clinical trial program evaluated tirzepatide in patients with type 2 diabetes across multiple Phase 3 trials. Key findings included HbA1c reductions of 1.87-2.58% (substantially larger than the 1.55% reduction seen with semaglutide 1 mg in head-to-head comparison), body weight reductions of 7.8-12.4 kg over 40-52 weeks, and a safety profile generally consistent with the GLP-1 agonist class.⁴

The SURPASS-2 trial was particularly significant because it directly compared tirzepatide against semaglutide 1 mg. Tirzepatide outperformed semaglutide on both HbA1c reduction and weight loss at all three dose levels tested — the first clinical demonstration that dual agonism produced superior metabolic outcomes to single-receptor agonism in humans.

SURMOUNT Program (Obesity)

The SURMOUNT program evaluated tirzepatide specifically for weight management in people without diabetes. SURMOUNT-1 showed mean weight reductions of 15.0-20.9% over 72 weeks — the largest reductions observed in any anti-obesity medication trial at the time of publication. The highest-dose group showed a mean reduction of 22.5% of body weight, with 36.2% of participants achieving ≥25% body weight reduction.⁵

These results significantly exceeded the outcomes seen with semaglutide 2.4 mg (Wegovy) in the comparable STEP trials, which showed ~15% mean weight loss. The differential was attributed to the additional metabolic effects of GIP receptor co-activation.

The research has begun to clarify what GIP receptor activation contributes beyond GLP-1 effects:

Adipose Tissue Biology. GIP receptors are expressed on adipocytes (fat cells), and GIP signaling appears to influence fat metabolism directly. Research by Samms et al. demonstrated that GIP receptor agonism in obese mice produced insulin sensitization in adipose tissue independent of body weight changes — an effect not seen with GLP-1 agonism.⁶

Energy Expenditure. Some preclinical data suggests that dual agonism may increase energy expenditure to a greater degree than GLP-1 agonism alone, though this has been more difficult to demonstrate conclusively in clinical studies.

Tolerability. Counterintuitively, adding GIP agonism to GLP-1 agonism may actually improve gastrointestinal tolerability. GIP has anti-emetic (anti-nausea) properties, and some researchers hypothesize that GIP co-activation partially offsets the nausea caused by GLP-1 receptor stimulation.

Bone Metabolism. GIP receptor activation has established effects on bone. GIP stimulates osteoblast activity and inhibits osteoclast activity, potentially preserving bone density during weight loss — a concern with rapid weight reduction interventions.

Mechanism Clarity. While the clinical outcomes are clear (dual agonism produces greater weight loss than single agonism), the precise molecular mechanisms responsible for the incremental benefit of GIP are still being elucidated.

Long-Term Data. The longest published tirzepatide trials extend to 72 weeks. Multi-year outcomes including weight maintenance, cardiovascular effects, and long-term safety are still being studied.

Weight Regain. Studies of GLP-1 agonist discontinuation have shown significant weight regain. Whether dual agonism changes this pattern is an important open question.⁷

Individual Variability. Not all participants respond equally. Understanding who benefits most from dual agonism versus GLP-1 alone is an active research area.

Cost and Access. The clinical versions of tirzepatide are expensive branded medications. Research-grade compounds like OSYRIS GLP-2 (T) provide researchers with tools to study dual agonism in preclinical models.

The OSYRIS catalog contains all three levels of incretin agonism: GLP-1 (S) for single-receptor research, GLP-2 (T) for dual-receptor research, and GLP-3 (R) for triple-receptor research (adding glucagon receptor agonism). This progression allows researchers to systematically investigate the incremental contribution of each additional receptor target.

Triple agonism (retatrutide class) adds glucagon receptor activation, which introduces hepatic fat oxidation and thermogenesis — effects absent from both single and dual agonists. Phase 2 data for retatrutide showed even larger weight reductions than tirzepatide, suggesting that the incremental receptor targeting pattern continues to produce incremental metabolic effects.⁸

This "stacking" of receptor targets is a central research question in metabolic pharmacology: how many receptors is too many, and where do the additional benefits plateau against the complexity of broader receptor activation?